Supervisory Board

He graduated from the Faculty of Law and Administration of the Warsaw University and completed postgraduate studies in the Warsaw School of Economics, Faculty of Business Valuation. His professional career was connected with the capital market within which he is an active investor both in private and regulated trading. He served as a member of the management board or a member of the supervisory board in many companies.

Dr. Kunsch has more than 30 years of experience in biopharmaceutical R&D, business development and life science venture capital investing. He obtained his Ph.D. in Immunology from The Pennsylvania State University College of Medicine and completed his post-doctoral fellowship at the Roche Institute of Molecular Biology where he studied retroviral gene regulation. After his post-doctoral fellowship, Chuck spent 4 years as a Project Leader at Human Genome Sciences and then joined AtheroGenics, Inc, as Vice President of Biology leading teams to advance several programs into the clinic for cardiovascular disease and chronic inflammatory diseases. Dr. Kunsch spent nearly 15 years at Abbott/AbbVie most recently as Managing Director at AbbVie Ventures where he served on the Boards of more than a dozen early-stage companies. Dr. Kunsch serves as the Vice Chair on the Board of Trustees for the Massachusetts Biomedical Initiative and on the Board of Trustees for the Pennsylvania State University Research Foundation.   

Krzysztof Samotij graduated from the Faculty of Basic Technical Problems of the Technical University of Wrocław and the State University of New York at Albany. In 1981 he was awarded a PhD degree in mathematics (analysis and probability theory) and started working at of the Technical University of Wrocław. He also lectured at the State University of New York at Albany and the University of Delaware. Krzysztof is the author of numerous academic works in the area of mathematics (functional and complex analysis). In 1996 he obtained investment advisor license no. 87. From July 1997 he was employed in WBK AIB Asset Management S.A., as an investment advisor, bond market manager. Since February 1998 he took the position of the President of the Management Board of WBK AIB Towarzystwo Funduszy Powierniczych S.A. From April 2001 he served as the Research and Development Director in WBK AIB Towarzystwo Funduszy Inwestycyjnych S.A. and investment advisor in WBK AIB Asset Management S.A. Between May 2002 and January 2011 he was the President of the Management Board of BZ WBK AIB Towarzystwo Funduszy Inwestycyjnych S.A. (presently: Santander TFI S.A.). At the end of this period it was the second (in terms of value of managed assets) company managing investment funds in Poland. Since 2011 he is self-employed as a sole trader. Krzysztof Samotij meets the independence criteria referred to in Article 129 sec. 3 of the Act on Certified Accountants, Audit Firms and Public Supervision and in the Good Practices of Companies Listed on the Warsaw Stock Exchange.

Maciej Wróblewski is a lawyer and specializes in corporate law, with a particular focus on mergers and acquisitions and capital markets advisory. He graduated from the Warsaw University and the Warsaw School of Economics. During his professional career he advised in public and private M&A transactions, in IPOs and secondary public offerings of public companies’ shares. Maciej Wróblewski is presently a partner in MJH Moskwa, Jarmul, Haładyj i Partnerzy – Adwokaci i Radcowie Prawni sp.p. Previously he was associated with Deloitte Legal Pasternak Korba Moskwa Jarmul i Wspólnicy Kancelaria Prawnicza sp. k. and Weil, Gotshal & Manges – Paweł Rymarz sp.k.

Robert Florczykowski is co-founder and manager of the Third Dot investment fund within Opoka TFI S.A. Previously, he managed global funds investing in technology companies and healthcare companies at the fund company PKO TFI S.A. Robert Florczykowski is a graduate of “Quantitative Methods in Economics and Information Systems” at the Warsaw School of Economics and “Mathematics” at the University of Warsaw. He also completed postgraduate studies in “Molecular Biology” at Jagiellonian University and “Postgraduate Studies in Accounting and Finance” at the Business School of Warsaw University of Technology, organized in cooperation with the ACCA institute. 

Dr Andrew Galazka is a senior biopharmaceutical executive with over 35 years of global experience in the industry (Biogen, GSK, Serono, Merck Serono). He completed his medical studies at the University of Cambridge and following clinical practice, specialized in pharmaceutical medicine (FFPM of the Royal College of Physicians [UK] and FMH [Switzerland]). He has senior management experience (SVP) in several disciplines, notably clinical development, regulatory affairs, and strategic marketing. He has led global development programs in multiple therapeutic areas including autoimmune and inflammatory diseases, neurology, oncology, infectious and tropical diseases. He has been responsible for bringing several products to the market, considered to be important advances in patient care.  

In recent years he was responsible for leading the global renaissance of Mavenclad®, the first oral ultra-short course medication for the treatment of multiple sclerosis, for which he and his team were awarded the prestigious Merck Award. 

He has served on the board of several early-stage biopharmaceutical companies and was also scientific advisor to the Neomed IV venture capital fund. He led the listing of Serono’s shares on the New York Stock Exchange, raising over $2 billion and tripling the company's valuation, and was subsequently awarded the Thomson Extel award. He currently serves as an independent board member and senior advisor to the biopharmaceutical industry, and lectures on drug development at the EPFL in Lausanne. He has authored over 60 publications in the field of drug development.